The 2027 spec roundup is built around three confirmed — or highly probable — release timelines: Avengers: Doomsday (May 2027, Marvel Studios), followed by Avengers: Secret Wars (May 2028); Sony's Spider-Man Cinematic Universe (Madame Web and Kraven sequels, Sinister Six rumors); and the DC Studios ecosystem launched by James Gunn's Superman (July 2025), extended by The Batman: Brave and the Bold announced for 2026. Priority key issues: Secret Wars #8 (1984, Spider-Man black costume), Amazing Spider-Man Annual #1 (1964, first Sinister Six), Kraven's Last Hunt via Spectacular Spider-Man #131 (1987), Action Comics #1 (1938, out of reach but benchmark value), Krypto in Adventure Comics #210 (1955), and Damian Wayne in Batman #655 (2006). Spec is a bet: diversification is the only discipline that pays off over time.
2027 is shaping up to be an inflection point for the adaptation comics market. On the Marvel Studios side, Avengers: Doomsday is set for May 2027 with Robert Downey Jr. in the role of Doctor Doom (Victor Von Doom) — a central event for MCU Phase 6, to be followed in May 2028 by Avengers: Secret Wars. On the Sony side, the Spider-Man Cinematic Universe (SSU) is navigating rough waters after the flops of Madame Web (February 2024) and Kraven the Hunter (December 2024), though Sinister Six rumors persist. And at DC Studios under James Gunn, the Superman reboot (July 2025) sets the stage for The Batman: Brave and the Bold — announced for 2026 — which will introduce Damian Wayne as Robin. This meta roundup synthesizes the key comics issues tied to each film and TV release calendar, with observed price ranges from May 2026 and a qualitative risk rating for each.
The methodology stays consistent throughout: cross-reference official release dates, confirmed cast members, associated key issues, optimal buying windows, and stop-loss targets on the resale side. The 2014–2024 track record shows that 60% of price gains happen in the 12 to 24 months before a film's release — which makes 2025–2026 the ideal entry window for 2027 release calendars. After that, the market digests the news and values pull back partially, as seen with the Eternals cycle in 2021 (a 35% drop over two years post-release). This roundup is a spoke of the Investing in Comics cluster and complements the 2026 spec articles published earlier this year.
Confirmed Marvel and DC Film and TV Schedule for 2026–2027
Building a 2027 spec roundup starts with separating official dates from rumors. Marvel Studios published its Phase 6 slate at D23 2024, then revised it in 2025. Three releases directly affect the 2027 spec market: Spider-Man: Brand New Day (July 2026), Avengers: Doomsday (May 2027), and Avengers: Secret Wars (May 2028). On the Disney+ side, Daredevil: Born Again Season 2 (spring 2027) and Wonder Man (already out in 2025) add to the slate, though the key issues for the latter have already been largely priced in by the market.
On the DC Studios side, James Gunn has been steering the new Gods and Monsters franchise since 2023, with Superman (July 2025) as its cornerstone. The announced slate includes Supergirl: Woman of Tomorrow (June 2026), Clayface (September 2026), and above all The Batman: Brave and the Bold — pushed to 2027 in some confirmations, still officially listed as 2026 in others — which will introduce Damian Wayne as Robin. The HBO Max series Lanterns is slated for 2026 and directly impacts key issues for Hal Jordan and John Stewart.
On the Sony Pictures side, the Spider-Man Cinematic Universe (SSU) is in the middle of a credibility crisis. After the successive flops of Morbius (2022), Madame Web (February 2024, estimated $100 million loss), and Kraven the Hunter (December 2024, both a critical and commercial failure), the studio has quietly restructured its strategy. Projects like Spider-Woman and Hypno-Hustler are on hold. A possible Sinister Six film is still mentioned in Sony corporate communications, but had no confirmed date as of May 2026. This gray area creates both risk (possible cancellation) and opportunity (key issues still underpriced).
The 2027 spec table therefore spans three time horizons: short-term (2026 releases where spec buying should be wrapping up now), medium-term (2027 releases where the optimal buying window is open through the end of 2026), and long-term (2028 releases and Sony rumors, where an early entry offers the best cost-to-potential ratio but the highest cancellation risk). The discipline is to allocate each portion of the budget to a specific horizon, without concentrating more than 35–40% on a single character or franchise.
For a full overview of MCU Phase 6, issue-by-issue coverage lives in MCU Phase 6 comics: how to anticipate key issues. For the general principles of the spec effect, see MCU and DCU adaptations: spec effect on values, which quantifies historical price increases from 2014 to 2024.
Avengers: Doomsday Spec — Secret Wars #8 and Battleworld
Avengers: Doomsday opens in theaters in May 2027. Robert Downey Jr. returns — this time as Doctor Doom (Victor Von Doom), an announcement made at San Diego Comic-Con 2024. The Marvel Studios cast also confirms part of the Avengers roster along with the Fantastic Four and the X-Men, making it a crossover event on the narrative scale of Infinity War. The film will serve as a bridge to Avengers: Secret Wars (May 2028), presumed to adapt the 1984 Jim Shooter crossover.
Marvel Super Heroes Secret Wars #8 (December 1984) is the most-discussed key issue in the roundup. The issue contains Spider-Man's first appearance in the black alien costume, a direct prologue to the Venom arc. CGC 9.8 copies were selling between $700 and $1,000 in early 2024, and were trading around $1,400–$1,900 in May 2026 — a partial rise already pricing in the Secret Wars announcement. CGC 9.6 sits between $500 and $750. Raw NM runs $80–$140. The ratio remains favorable if the film faithfully adapts the black costume arc, which has not yet been confirmed.
Marvel Super Heroes Secret Wars #1 (May 1984) is the other core piece. The issue launches the original crossover and introduces the Battleworld event. CGC 9.8 between $380 and $580 in May 2026, CGC 9.6 between $200 and $290, raw NM between $35 and $60. An accessible issue whose value tracks directly with official announcements. If Battleworld is the central arena of the 2028 film — as production leaks suggest — this issue could outperform.
On Doctor Doom, the classic key issues occupy an established price tier. Fantastic Four #5 (July 1962, first appearance of Victor Von Doom) is out of reach for most spec collectors: CGC 6.0 between $25,000 and $38,000 in 2026, CGC 7.0 exceeding $60,000. Spec on golden and early silver age books doesn't work the same way as on bronze and copper age: values are already at their ceiling, and post-film gains tend to be modest percentages compared to a bronze age sleeper.
The Doom sweet spot for 2027 lies in copper and modern age: Secret Wars #10 (February 1985), with Doom going head-to-head against the Beyonder — CGC 9.8 around $280–$400; Books of Doom #1 (January 2006) by Ed Brubaker — CGC 9.8 around $60–$90, a potential sleeper; and Infamous Iron Man #1 (December 2016), in which Doom takes on the Iron Man armor — CGC 9.8 between $80 and $130, an obvious narrative tie-in to the RDJ casting choice. See modern comics 2020–2026: where to invest for the methodology applied to copper and modern age books.
Spider-Man Cinematic Universe Spec — Spectacular Spider-Man #131 and the Original Sinister Six
Sony's Spider-Man Cinematic Universe (SSU) remains the most volatile part of the roundup. After the failures of Madame Web (February 2024) and Kraven the Hunter (December 2024), no new SSU project has a confirmed release date. Yet Sony retains the rights to hundreds of Spider-Man characters and continues to publicly reference a Sinister Six in development. That gray area creates interesting entry points for disciplined collectors.
Amazing Spider-Man Annual #1 (1964) contains the first appearance of the original Sinister Six, assembled by Doctor Octopus: Doc Ock, Vulture, Electro, Sandman, Mysterio, and Kraven. If Sony ever makes this film, this issue is ground zero for the spec. CGC 7.0 between $1,800 and $2,600 in May 2026, CGC 8.0 between $3,500 and $5,000. Raw VF between $350 and $600. The issue is already trading at its established silver age value — any spec upside depends on Sony announcing an official release date.
Spectacular Spider-Man #131 (October 1987) closes out the Kraven's Last Hunt arc, considered one of the most important Spider-Man storylines of the 1980s. Even though Sony's Kraven the Hunter (December 2024) flopped, the comics arc retains demand that exists independently of the film. CGC 9.8 between $90 and $150 in May 2026, raw NM between $12 and $22. The first issue of the arc, Web of Spider-Man #31 (October 1987), tracks the same curve. Paradoxically, the post-flop Kraven spec offers a low entry point with limited downside — the arc remains a cult classic regardless of the film's fate.
Amazing Spider-Man #15 (August 1964) contains the first appearance of Kraven the Hunter. CGC 6.0 between $1,200 and $1,800 in 2026, CGC 7.0 between $2,200 and $3,200. Raw VF between $250 and $400. The 2024 film flop slightly compressed values (estimated 12–18% decline over 12 months), but the issue remains a solid silver age key. Risk: if Kraven is definitively shelved by Sony and doesn't appear in the MCU either, the value could stagnate for 3–5 years.
On Madame Web, the February 2024 film flop crushed associated key issue values. Amazing Spider-Man #210 (November 1980, first Madame Web) dropped from $120–$180 CGC 9.8 at end of 2023 to $80–$130 in May 2026 — a decline of 30 to 35%. It's a textbook case of spec downside risk: a film that underperforms durably devalues its associated key issue. See undervalued comics 2026: sleeper issues for an analysis of comics that remain attractive even without a film catalyst.
SSU spec for 2026–2027 calls for particular discipline: avoid allocating more than 10–15% of total spec budget to the Sony ecosystem until Sony confirms a release date for a new film. Better to underweight the SSU in a spec portfolio and potentially miss a rebound if Sinister Six ever materializes, than to overcommit to an uncertain pipeline.
DC Studios Superman 2025 — Action Comics #1 and Krypto
James Gunn's Superman released on July 11, 2025, and generated a measurable price increase across classic Superman key issues. The film — the first installment of the rebooted DC Universe (DCU) — stars David Corenswet as Clark Kent, Rachel Brosnahan as Lois Lane, and gives Krypto the Super-Dog a central role. The retrospective analysis, ten months after release, lets us calibrate post-event spec rather than predictive spec.
Action Comics #1 (June 1938), Superman's first appearance, remains the most famous book in the comics market. CGC 6.0 has exceeded $3.5 million at public auction, and CGC 8.0 has crossed the $6 million mark at Heritage. The issue is far beyond the reach of individual spec, but it serves as the benchmark for calibrating the Superman market. The 2024–2026 price increase on grade 4.0–6.0 copies is estimated at 15–22%. These value levels are reserved for a narrow circle of institutional collectors.
Adventure Comics #210 (March 1955) contains the first appearance of Krypto, the Superdog. With Krypto's central role in Gunn's 2025 film, this issue has surged. CGC 5.0 between $1,800 and $2,600 in May 2026, versus $800–$1,200 at end of 2023 — a gain of 100 to 120%. CGC 4.0 between $1,200 and $1,700. Raw VF between $250 and $400. The issue perfectly illustrates the spec mechanism: a supporting character steps into the spotlight thanks to a confirmed casting, and the value of the original key issue realigns accordingly.
Superman #1 (Summer 1939), the first standalone issue, follows the same dynamic but at a higher price tier. CGC 4.0 between $30,000 and $45,000 in May 2026. CGC 6.0 between $90,000 and $130,000. The 2024–2026 gain is estimated at 18–25%, driven by the broader DCU reboot more than by Superman alone.
Action Comics #252 (May 1959) contains the first appearance of Supergirl. With Supergirl: Woman of Tomorrow announced for June 2026 (Milly Alcock in the role), this issue is the hottest secondary DC key in the roundup. CGC 5.0 between $12,000 and $17,000, CGC 6.0 between $20,000 and $28,000. Raw VF between $1,800 and $2,800. The optimal buying window has passed — most of the anticipated 2026 run-up is already baked into the price. But a second wave is likely at release, which may justify holding for current owners.
Action Comics #1000 (June 2018), for modern collectors, is an editorial milestone with numerous variants. Cover A in CGC 9.8 around $50–$80, decade-themed variants between $60 and $200. An accessible modern sleeper tied to the Superman franchise that DC is positioning as its flagship for the 2025–2035 decade. See the complete strategic guide to investing in comics for the overarching methodology.
Batman: Brave and the Bold + Robin Spec
The Batman: Brave and the Bold is slated in the DC Studios lineup for 2026, directed by Andy Muschietti. The film introduces Damian Wayne as Robin — son of Batman and Talia al Ghul. The announcement already triggered a measurable spec cycle on Damian key issues and across Grant Morrison's 2006–2013 run. The release could slip to 2027 depending on Warner Bros. scheduling decisions, which widens the 2026 buying window.
Batman #655 (September 2006) contains Damian Wayne's first cameo appearance in Grant Morrison's run. CGC 9.8 between $280 and $420 in May 2026, up 60–80% over 18 months. CGC 9.6 between $130 and $200. Raw NM between $25 and $45. This issue is the primary spec entry point for Damian. Risk: if Brave and the Bold is pushed to 2028, the value could plateau without further gains until a firm date is confirmed.
Batman #656 (October 2006) contains Damian's first full appearance. The cameo vs. full-appearance distinction matters in the CGC market: both issues trade at comparable levels, with a slight premium on #655. CGC 9.8 between $220 and $340 in May 2026. The spec on this pair of issues is among the most predictable in the DC roundup.
Batman Incorporated #8 (March 2013) marks Damian's death in Morrison's run — a major narrative event. Though the death was eventually reversed (as comics go), the issue remains an established key. CGC 9.8 between $90 and $150 in May 2026. Post-2026 film spec could push these prices higher if the film's narrative draws on the Damian death-and-resurrection arc.
For older Robins, the market has already absorbed most of the gains. Detective Comics #38 (April 1940, first Dick Grayson Robin) in CGC 4.0 between $30,000 and $45,000 — an established floor. Detective Comics #647 (August 1992, first Stephanie Brown) is accessible: CGC 9.8 between $80 and $130, a sleeper if she gets an adaptation down the line. See pre-ordering comics: an investment strategy for the methodology applied to pre-announcement buying.
The Brave and the Bold spec also covers the Outsiders and Detective Chimp if the film expands its casting. Adventure Comics #103 (April 1946, first Detective Chimp) in CGC 6.0 between $1,200 and $1,800 — a niche sleeper. The price-to-volume ratio on this issue makes it illiquid: it can take six months to find a buyer even at market value.
Meta Collector Strategy for 2027
Distilling a 2027 roundup into a collector strategy requires ranking the bets by probability of occurrence and time horizon. Four pillars structure a sound meta approach. The first pillar is separating confirmed releases from speculative ones. For 2027, Avengers: Doomsday has a confirmed date and partial cast. Spider-Man: Brand New Day has a confirmed date. The Batman: Brave and the Bold has a communicated date, but Warner Bros.'s track record warrants planning for a possible slip. Sinister Six from Sony is not confirmed.
The second pillar is diversifying across franchises. Concentrating 100% of a 2027 spec budget on Marvel Studios is risky if even one announcement gets delayed. The allocation seen among disciplined collectors tends to run around 50% Marvel, 30% DC, 15% Sony (underweighted given the 2024 flops), and 5% other (Image, Boom, indie as an option). This allocation gets recalibrated every six months based on announcements. For portfolio discipline, see modern comics 2020–2026.
The third pillar is calibrating the buying window to the time horizon. For 2026 releases (Brand New Day, Brave and the Bold, Supergirl), the optimal window is already underway and closes during 2026. For 2027 releases (Doomsday, Daredevil Season 2), the 2025–2026 window is ideal. For 2028 releases (Secret Wars, possible X-Men reboot), the 2026–2027 window is opening now. Buying outside these windows means either buying too early (tying up capital) or too late (catching the top of the cycle).
The fourth pillar is defining an exit plan before you buy. Three empirical thresholds apply: +50% gross on CGC 9.6 (moderate sell target), +100% gross on an established key issue (classic target), or a hard price ceiling (e.g., sell as soon as CGC 9.8 crosses $1,500). After a film releases, watch for 4 to 8 weeks before deciding: if the value drops more than 15% within the first six weeks post-release, consider an immediate sale. This discipline is detailed in pre-ordering and investment strategy.
Meta tracking requires a dedicated tool. A value recorded in January 2026 is stale by September. A Comics Manager with live valuations (see comics collection app) provides the refresh rate needed to manage an 18-to-36-month hold. Without it, collectors discover the gain three months after the peak and miss the window. For a broader view of the historical spec effect from 2014 to 2024, see MCU and DCU adaptations: spec effect.
One final rule of thumb: across a 2027 spec portfolio of 8 to 12 bets spread across three franchises, the success rate observed among disciplined collectors runs 55–65%. The big wins (+100% to +300%) on 2 to 3 bets offset the losses (−15% to −35%) on 3 to 4 others. The overall net return (after Heritage, eBay, and CGC grading fees) has averaged around 15–25% annualized over the 2014–2024 decade, pre-tax. After US capital gains tax, expect 10–18% annualized — still competitive versus a diversified equity position, but with much lower liquidity.
FAQ — 2027 Spec Keys: Marvel and DC Films and Series
What are the priority key issues for Avengers: Doomsday 2027?
Three issues anchor the Doomsday spec. Marvel Super Heroes Secret Wars #8 (1984) for the Spider-Man black costume and the Battleworld narrative link — CGC 9.8 between $1,400 and $1,900 in May 2026. Secret Wars #1 (1984), CGC 9.8 between $380 and $580, a more accessible entry point. On Doom, Books of Doom #1 (2006) and Infamous Iron Man #1 (2016) remain affordable copper and modern age sleepers ($60–$130 CGC 9.8), tied to the RDJ-as-Doom arc announced at San Diego Comic-Con 2024.
Does the Kraven the Hunter flop in 2024 doom the Kraven key issues?
No, but it temporarily devalues them. Amazing Spider-Man #15 (1964, first Kraven) dropped 12–18% over 12 months post-flop but remains a solid established silver age key. Spectacular Spider-Man #131 (1987, conclusion of Kraven's Last Hunt) has held its value ($90–$150 CGC 9.8) because the arc remains a cult classic regardless of the film. The takeaway for spec: a flop temporarily crushes values but doesn't destroy key issues with intrinsic narrative importance. Diversification is the only real protection against this type of risk.
Should you buy Action Comics #1 if you have the budget in 2026?
The question is largely academic: CGC 6.0 exceeds $3.5 million, which puts the issue well outside the scope of any individual spec decision. For Superman spec in 2025–2026, the most interesting price-to-potential ratios are found in Adventure Comics #210 (first Krypto, CGC 5.0 between $1,800 and $2,600, already up 100% thanks to the Gunn film) and Action Comics #252 (first Supergirl, CGC 5.0 between $12,000 and $17,000, tied to the 2026 film). Action Comics #1 is a value benchmark for the Superman market — not a spec target.
What is the best buying window for 2027 spec?
For 2027 releases (Doomsday, Daredevil Season 2, and Brave and the Bold if it slips to 2027), the optimal window runs from end of 2024 through end of 2026. Buying in 2025 or the first half of 2026 maximizes remaining upside potential before late-2026 media coverage crystallizes the market. For 2028 releases (confirmed Secret Wars, rumored X-Men reboot), the 2026–2027 window is opening now. Beyond these windows, the risk-reward ratio deteriorates quickly.
Is the Sony Spider-Man Cinematic Universe still worth speccing on in 2026?
With caution and an underweight position. The successive flops of Morbius, Madame Web, and Kraven the Hunter have damaged the SSU's credibility. Allocating more than 10–15% of total spec budget to the SSU would be excessive risk. That said, Sony still holds the Sinister Six rights and continues to reference the project: Amazing Spider-Man Annual #1 (1964, first Sinister Six) remains an established silver age key whose value is largely independent of SSU fortunes. SSU spec is built on underweighting — focusing on books whose intrinsic value holds up even if the film never gets made.